Higher dosing of alglucosidase alfa improves outcomes in children with Pompe disease: a clinical study and review of the literature
- 1 May 2020
- journal article
- review article
- Published by Elsevier BV in Genetics in Medicine
- Vol. 22 (5), 898-907
- https://doi.org/10.1038/s41436-019-0738-0
Abstract
No abstract availableThis publication has 35 references indexed in Scilit:
- Reference values for the 6-minute walk test in healthy children and adolescents in SwitzerlandBMC Pulmonary Medicine, 2013
- Skeletal muscle pathology of infantile Pompe disease during long-term enzyme replacement therapyOrphanet Journal of Rare Diseases, 2013
- The emerging phenotype of long-term survivors with infantile Pompe diseaseGenetics in Medicine, 2012
- Percent-Predicted 6-Minute Walk Distance in Duchenne Muscular Dystrophy to Account for Maturational InfluencesPLoS Currents, 2012
- Improvement of Bilateral Ptosis on Higher Dose Enzyme Replacement Therapy in Pompe DiseaseJournal of Neuro-Ophthalmology, 2010
- Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infantsMolecular Genetics and Metabolism, 2010
- Pompe Disease in Infants: Improving the Prognosis by Newborn Screening and Early TreatmentPEDIATRICS, 2009
- Early Treatment With Alglucosidase Alfa Prolongs Long-Term Survival of Infants With Pompe DiseasePediatric Research, 2009
- Maximal Tongue Strength in Typically Developing Children and AdolescentsDysphagia, 2009
- Clinical manifestation and natural course of late-onset Pompe's disease in 54 Dutch patientsBrain, 2005